Liver transplantation (LTX) Surgery Transplanted organ and tissue status
Conditions
Interventions
Verum group receives intravenous 250 ml glycine-solution (4.4%), starting prior to reperfusion of liver transplant during surgery and once daily during the first week after LTX.
Placebo group receives
Sponsors
University of Heidelberg (Germany)
Eligibility
Inclusion criteria
Inclusion criteria: Liver transplant recipients
Exclusion criteria
Exclusion criteria: Does not match inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Added 24/08/09: 1. Peak levels of both aspartat-amino-transaminase (AST) and alanine-amino-transaminase (ALT) as surrogates for the progression of liver related injury 2. Graft and patient survival up to 2 years after transplantation | — |
Secondary
| Measure | Time frame |
|---|---|
| Added 24/08/09: 1. Effect of glycine on liver injury based on liver biopsy immediately after re-arterialisation (according to pathological report) 2. Total blood flow in portal vein and common hepatic artery 1 hour after reperfusion 3. Graft injury based on both AST and ALT serum levels (area under the curve [AUC]) 4. Incidence of early graft failure based on peak of transaminases or clotting factor support 5. Early onset of graft dysfunction based on Quick's value 5. Serum bilirubin (AUC) 7. CyA-induced nephrotoxicity based on retention parameters during the first eight days after transplantation (AUC) | — |
Countries
Germany
Outcome results
None listed